Comparison of cardiac and pulmonaryspecific quality-of-life measures in pulmonary arterial hypertension

European Respiratory Journal

Volumn 38, Issue 3, 2011, Pages 608-616

  Chen, H ^a   De Marco, T ^a   Kobashigawa, E A ^a   Katz, P P ^a   Chang, V W ^a   Blanc, P D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pulmonary hypertension; Quality of life

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN;

ADULT; AIRWAYS QUESTIONNAIRE 20; ARTERY CATHETERIZATION; ARTICLE; BORG DYSPNOEA INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PHYSICAL CAPACITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT PARAMETERS; SHORT FORM 36; WALKING; WORLD HEALTH ORGANIZATION; AGED; BREATHING; COMPARATIVE STUDY; HEMODYNAMICS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RESPIRATION;

EID: 80053071994     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00161410     Document Type: Article

References (30)

1. Garratt A, Schmidt L, Mackintosh A, et al. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002; 324: 1417.
2. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
3. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788. (Pubitemid 34925627)
4. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249. (Pubitemid 40246523)
5. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
6. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5: 623-630. (Pubitemid 352031535)
7. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006; 28: 808-815. (Pubitemid 46332003)
8. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
9. Chen H, Eisner MD, Teehankee CM, et al. Environmental tobacco smoke and health status in patients with pulmonary arterial hypertension. Chest 2005; 128: 364S.
10. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
11. Rector RS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Failure 1987; 1: 198-209.
12. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124: 1017-1025.
13. Quirk FH, Jones PW. Repeatability of two new short airways questionnaires. Thorax 1994; 49: 1075.
14. Alemayehu B, Aubert RE, Feifer RA, et al. Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value Health 2002; 5: 436-441.
15. Chen H, Eisner MD, Katz PP, et al. Measuring disease-specific quality of life in obstructive airway disease: validation of a modified version of the airways questionnaire 20. Chest 2006; 129: 1644-1652. (Pubitemid 43894998)
16. Barley EA, Quirk FH, Jones PW. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir Med 1998; 92: 1207-1214. (Pubitemid 28502363)
17. Hajiro T, Nishimura K, Jones PW, et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1874-1878. (Pubitemid 29275057)
18. McKenna SP, Doughty N, Meads DM, et al. The Cambridge PulmonaryHypertensionOutcome Review(CAMPHOR): ameasureof health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103-115. (Pubitemid 43097591)
19. Gomberg-Maitland M, Thenappan T, Rizvi K, et al. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008; 27: 124-130.
20. Davis JA. Elementary Survey Analysis. Englewood Cliffs, Prentice-Hall; 1971.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Edn. Hillsdale, Lawrence Erlbaum Associates Inc., 1988.
22. De Vaus DA. Analyzing Social Science Data: 50 Key Problems in Data Analysis. London, Sage Publications Ltd. 2002.
23. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
24. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
25. Zlupko M, Harhay MO, Gallop R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008; 102: 1431-1438.
26. Chua R, Keogh AM, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 2006; 36: 705-710. (Pubitemid 44563431)
27. Bennett SJ, Oldridge NB, Eckert GJ, et al. Comparison of quality of life measures in heart failure. Nurs Res 2003; 52: 207-216.
28. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384-391. (Pubitemid 32738745)
29. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-1487. (Pubitemid 30452465)
30. Coteur G, Feagan B, Keininger DL, et al. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009; 29: 1032-1041.